US EditionPCMA Statement on Today’s Federal Trade Commission/Department of Justice Listening Session on Big Pharma’s Anti-Competitive Behavior
Summary by PCMA
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
PCMA Statement on Today’s Federal Trade Commission/Department of Justice Listening Session on Big Pharma’s Anti-Competitive Behavior
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released the following statement on the “Anticompetitive Conduct by Pharmaceutical Companies Impeding Generic or Biosimilar Competition” listening session, held jointly by the Federal Trade Commission (FTC), Department of Justice (DOJ), Department of Health and Human Services (HHS), and the Department of Commerce (DOC). “We applaud the announcement by FTC Chairman A…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
